Author: Ken Dropiewski

JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice

Guide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced […]

Alleviant Medical Closes $75M in Financing; Receives FDA IDE Approval for Pivotal Clinical Trial

Novel technology shows potential to treat heart failure—leading cause of hospitalizations worldwide—with less invasive approach January 26, 2023 09:00 AM Eastern Standard Time AUSTIN, Texas–(BUSINESS WIRE)–Alleviant Medical, Inc., a privately-held medical device company developing a no-implant interatrial shunt for heart failure, today announced the closing of a $75 million equity […]

Clinical Study Shows Vista.ai Significantly Reduces Cardiac MRI Scan Time

Real-world cardiac MRI data gathered at Brigham and Women’s Hospital to be discussed at 26th Annual SCMR Scientific Sessions SAN DIEGO, Jan. 26, 2023 /PRNewswire/ — Vista.ai, a pioneer and leader in automated MRI solutions, today announced results from a clinical adaptation study on the company’s One Click MRI™ software, led by Dr. Raymond Kwong, Director, […]

XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

-No serious adverse events related to drug product were reported -Patients demonstrated improvements in exercise capacity and reductions in episodes of chest pain -Cardiac imaging results provide mechanistic evidence supporting the therapeutic potential of XC001 in cardiovascular disease WAYNE, Pa.–(BUSINESS WIRE)–XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies […]

Cardiac Dimensions Appoints Angie Swenson as Vice President, Clinical Operations

KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the appointment of Angie Swenson as Vice President of Clinical Operations. Ms. Swenson has spent most of the last 20 years leading clinical trials in […]

Elucid Appoints Scott Burger as Chief Commercial Officer

Cardiovascular industry veteran will help propel Elucid’s next generation AI-powered software to the forefront of disease risk prediction and management BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Scott Burger as chief commercial officer. […]

MedAlliance leads US Sirolimus DEB race: First US Patient enrolled into SELUTION SLR Coronary Sirolimus DEB Study

GENEVA, Jan. 25, 2023 /PRNewswire/ — The first US patient has been enrolled at MedStar Washington Hospital Center in the SELUTION4ISR study evaluating SELUTION SLR™ to support FDA approval. This milestone follows Investigational Device Exemption (IDE) approval in the US in October 2022. SELUTION SLR is the first sustained limus release coronary drug-eluting balloon […]

New Initiative Aims to Reverse the Alarming Rise in Cardiovascular Deaths

Cardiovascular Disease is the Number One Cause of Death Nationwide WASHINGTON, Jan. 25, 2023 /PRNewswire/ — The number of cardiovascular deaths is on the rise again after a decades-long decline. As organizations working to advance cardiovascular health and the interests of medically underserved communities, the Foundation of the National Lipid Association and the […]

Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook

Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34 Continues to strengthen portfolio with steady cadence of new product approvals ABBOTT PARK, Ill., Jan. 25, 2023 /PRNewswire/ — Abbott […]

Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI

MINNEAPOLIS–(BUSINESS WIRE)–Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare. Under the terms of the MOU, GE HealthCare and Imricor intend to collaborate to interface […]